Company news

Alnylam Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

April 6, 2024

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

March 19, 2024

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

March 12, 2024

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

March 4, 2024

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

February 26, 2024

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

February 14, 2024

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results

January 28, 2024

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

January 8, 2024

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates

January 6, 2024

Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

December 12, 2023

Alnylam to Webcast Virtual R&D Day

December 5, 2023

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

November 29, 2023

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

November 10, 2023

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity

November 1, 2023

Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year

October 25, 2023

Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

October 24, 2023

Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine

October 24, 2023

Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results

October 18, 2023

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

October 8, 2023

Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023

October 5, 2023

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 12, 2023

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 12, 2023

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

September 6, 2023

Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity

August 2, 2023

Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk

July 23, 2023

Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results

July 19, 2023

Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

July 18, 2023

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

July 16, 2023

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

June 29, 2023

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

June 4, 2023

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

May 19, 2023

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

May 3, 2023

Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference

May 2, 2023

Alnylam Issues 2022 Corporate Responsibility Report

May 2, 2023

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 25, 2023

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 25, 2023

Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results

April 19, 2023

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

March 8, 2023

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

March 7, 2023

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

February 22, 2023

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

February 20, 2023

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

February 1, 2023

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

January 7, 2023

Alnylam Announces Updates to its Board of Directors

January 4, 2023

Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes

December 20, 2022

Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

December 14, 2022

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

December 7, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.